The use of FDG-PET in assessing axillary lymph node status in breast cancer: A systematic review and meta-analysis of the literature

Breast Cancer Research and Treatment

Volumn 123, Issue 1, 2010, Pages 281-290

  Peare, Rebecca ^a   Staff, R T ^a   Heys, S D ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Axilla; Breast cancer; PET; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAMMOGRAPHY; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; AREA UNDER THE CURVE; AXILLA; BREAST TUMOR; CANCER STAGING; DIAGNOSTIC USE; FEMALE; LYMPH NODE; PATHOLOGY; PROCEDURES; SCINTISCANNING;

AREA UNDER CURVE; AXILLA; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 77955771592     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0771-9     Document Type: Article

References (43)

1. CL Carter C Allen DE Henson 1989 Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 181 187 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H 1:STN:280:DyaL1M%2FovFCqug%3D%3D 2910416 (Pubitemid 19032001)
2. LLM Shek W Godolphin 1988 Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis Cancer Res 48 5565 5569 1:STN:280: DyaL1czislOgtA%3D%3D 3416309
3. JM Ververs RM Roumen AJ Vingerhoets,, et al. 2001 Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer Eur J Cancer 37 991 999 10.1016/S0959-8049(01) 00067-3 1:STN:280:DC%2BD3M3jvFKqug%3D%3D 11334724 (Pubitemid 32397684)
4. AD Purushotham S Upponi MB Klevesath,, et al. 2005 Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial J Clin Oncol 23 4312 4321 10.1200/JCO.2005.03.228 15994144 (Pubitemid 46209968)
5. JW Jakub S Pendas DS Reintgen 2003 Current status of sentinel lymph node mapping and biopsy: facts and controversies Oncologist 8 59 68 10.1634/theoncologist.8-1-59 12604732 (Pubitemid 36232356)
6. RC Martin II A Chagpar CR Scoggins,, et al. 2005 Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer Ann Surg 241 1005 1012 10.1097/01.sla.0000165200.32722.02 15912050 (Pubitemid 40733976)
7. BJ Chae JS Bae BJ Kang,, et al. 2009 Positron emission tomography-computed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer Jpn J Clin Oncol 39 284 289 10.1093/jjco/hyp019 19318373
8. N Taira S Ohsumi D Takabatake,, et al. 2009 Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging Jpn J Clin Oncol 39 16 21 10.1093/jjco/hyn120 18997183
9. D Fuster J Duch P Paredes,, et al. 2008 Preoperative staging of large primary breast cancer with [18F]Fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures J Clin Oncol 26 29 4746 4751 10.1200/JCO.2008.17.1496 18695254
10. S Ueda H Tsuda H Asakawa,, et al. 2008 Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer BMC Cancer 8 165 10.1186/1471-2407-8-165 18541009 (Pubitemid 351877805)
11. WT Yang HT Le-Petross H Macapinlac,, et al. 2008 Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings Breast Cancer Res Treat 109 417 426 10.1007/s10549-007-9671-z 1:CAS:528:DC%2BD1cXlvVCgtr0%3D 17653852 (Pubitemid 351692058)
12. U Veronesi C De Cicco VE Galimberti,, et al. 2007 A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases Ann Oncol 18 473 478 10.1093/annonc/mdl425 1:STN:280: DC%2BD2szlt1ajtg%3D%3D 17164229 (Pubitemid 46359625)
13. A Chung D Liou S Karlan,, et al. 2006 Preoperative FDG-PET for axillary metastases in patients with breast cancer Arch Surg 141 783 788 10.1001/archsurg.141.8.783 16924086 (Pubitemid 44268521)
14. A Gil-Rendo G Zornoza MJ Garcia-Velloso,, et al. 2006 Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer Br J Surg 93 707 712 10.1002/bjs.5338 1:STN:280:DC%2BD283ptVaitQ%3D%3D 16622900 (Pubitemid 43886022)
15. R Kumar H Zhuang M Schnall,, et al. 2006 FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer Nucl Med Commun 27 231 236 10.1097/00006231-200603000-00005 16479242 (Pubitemid 44391810)
16. MK Fehr R Hornung Z Varga,, et al. 2004 Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy Breast J 10 89 93 10.1111/j.1075-122X.2004.21455.x 15009033 (Pubitemid 38375027)
17. PJ Lovrics V Chen G Coates,, et al. 2004 A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer Ann Surg Oncol 11 846 853 10.1245/ASO.2004.11.033 15313737 (Pubitemid 40568812)
18. RL Wahl BA Siegel RE Coleman,, et al. 2004 Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group J Clin Oncol 22 277 285 10.1200/JCO.2004.04.148 14722036 (Pubitemid 41095092)
19. G Zornoza MJ Garcia-Velloso J Sola,, et al. 2004 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer Eur J Surg Oncol 30 15 19 10.1016/j.ejso.2003.10.010 1:STN:280:DC%2BD2c%2Fjslaisw%3D%3D 14736517 (Pubitemid 38180986)
20. U Guller EU Nitzsche U Schirp,, et al. 2002 Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treat 71 171 173 10.1023/A:1013828710301 11881913 (Pubitemid 34145374)
21. JJ van der Hoeven OS Hoekstra EF Comans,, et al. 2002 Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer Ann Surg 236 619 624 10.1097/00000658- 200211000-00012 12409668 (Pubitemid 35246894)
22. M Greco F Crippa R Agresti,, et al. 2001 Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management J Natl Cancer Inst 93 630 635 10.1093/jnci/93.8.630 1:STN:280:DC%2BD3Mzht1KntA%3D%3D 11309439
23. H Schirrmeister T Kuhn A Guhlmann,, et al. 2001 Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures Eur J Nucl Med 28 351 358 10.1007/s002590000448 1:CAS:528:DC%2BD3MXitFeiu7o%3D 11315604
24. M Ohta Y Tokuda Y Saitoh,, et al. 2000 Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer Breast Cancer 7 99 103 10.1007/BF02967197 1:STN:280:DC%2BD3cvnvFWrsQ%3D%3D 11029780
25. K Yutani E Shiba H Kusuoka,, et al. 2000 Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis J Comput Assist Tomogr 24 274 280 10.1097/00004728-200003000-00017 1:STN:280:DC%2BD3c3hsVGltA%3D%3D 10752892 (Pubitemid 32206208)
26. K Yutani M Tatsumi E Shiba,, et al. 1999 Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis J Nucl Med 40 1003 1008 1:STN:280: DyaK1MznvFertQ%3D%3D 10452318
27. IC Smith KN Ogston P Whitford,, et al. 1998 Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose Ann Surg 228 220 227 10.1097/00000658-199808000-00012 1:STN:280:DyaK1czns1CisQ%3D%3D 9712568 (Pubitemid 30191718)
28. LP Adler PF Faulhaber KC Schnur,, et al. 1997 Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET Radiology 203 323 327 1:STN:280:DyaK2s3mvVOgtg%3D%3D 9114082
29. N Avril J Dose F Janicke,, et al. 1996 Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose J Natl Cancer Inst 88 1204 1209 10.1093/jnci/88.17.1204 1:STN:280:DyaK28znsVegug%3D%3D 8780629
30. CI Utech CS Young PF Winter 1996 Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry Eur J Nucl Med 23 1588 1593 10.1007/BF01249621 1:STN:280:DyaK2s%2FotlKlug%3D%3D 8929312 (Pubitemid 27023055)
31. JP Crowe Jr LP Adler RR Shenk,, et al. 1994 Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings Ann Surg Oncol 1 132 140 10.1007/BF02303557 7834438
32. AD Murray RT Staff TW Redpath,, et al. 2002 Dynamic contrast enhanced MRI of the axilla in women with breast cancer: comparison with pathology of excised nodes Br J Radiol 75 220 228 1:STN:280:DC%2BD387pvFWktw%3D%3D 11932214
33. T Uematsu M Sano K Homma 2001 In vitro high-resolution helical CT of small axillary lymph nodes in patients with breast cancer: correlation of CT and histology Am J Roentgenol 176 1069 1074 1:STN:280:DC%2BD3M3hslaitA%3D%3D
34. DE March RJ Wechsler AB Kurtz,, et al. 1991 CT-pathologic correlation of axillary lymph nodes in breast carcinoma J Comput Assist Tomogr 15 440 444 10.1097/00004728-199105000-00017 1:STN:280:DyaK3M3isFaquw%3D%3D 2026806
35. FM Chappell GM Raab JM Wardlaw 2009 When are summary ROC curves appropriate for diagnostic meta-analyses? Stat Med 28 2653 2668 10.1002/sim.3631 1:STN:280:DC%2BD1Mrls1Cnuw%3D%3D 19591118
36. TA Heusner S Kuemmel L Umutlu,, et al. 2008 Breast cancer staging in a single session: whole-body PET/CT mammography J Nucl Med 49 1215 1222 10.2967/jnumed.108.052050 18632831
37. F Crippa R Agresti VD Donne,, et al. 1997 The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan Tumori 83 542 543 1:STN:280: DyaK2szmvFGhtQ%3D%3D 9226015
38. TR DeGrado TG Turkington JJ Williams,, et al. 1994 Performance characteristics of a whole-body PET scanner J Nucl Med 35 1398 1406 1:STN:280:DyaK2czit1WjtQ%3D%3D 8046501
39. O Mawlawi DA Podoloff S Kohlmyer,, et al. 2004 Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes J Nucl Med 45 1734 1742 15471842
40. S Surti JS Karp 2004 Imaging characteristics of a 3-dimensional GSO whole-body PET camera J Nucl Med 45 1040 1049 1:CAS:528:DC%2BD2cXnsFygtro%3D 15181139
41. J Zamora V Abraira A Muriel,, et al. 2006 Meta-DiSc: a software for meta-analysis of test accuracy data BMC Med Res Methodol 6 31 10.1186/1471-2288-6-31 16836745 (Pubitemid 44285240)
42. S Walter 2002 Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data Stat Med 21 1237 1256 10.1002/sim.1099 1:STN:280:DC%2BD38zmtV2huw%3D%3D 12111876 (Pubitemid 34467232)
43. K Scheidhauer A Scharl U Pietrzyk,, et al. 1996 Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability Eur J Nucl Med 23 618 623 10.1007/BF00834522 1:STN:280: DyaK283mvF2msA%3D%3D 8662094 (Pubitemid 26187210)